Related Experiment Video
Updated: Jul 29, 2025
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study
Michael J Hanley1, Paul Diderichsen2, Benjamin Rich2,3
1Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Abstract:
Optimizing Ponatinib Treatment in CP-CML (OPTIC) was a randomized, phase II dose-optimization trial of ponatinib in chronic phase-chronic myeloid leukemia (CP-CML) resistant to ≥ 2 tyrosine kinase inhibitors or with T315I mutation. Patients were randomized to starting doses of 45-, 30-, or 15-mg ponatinib once daily. Patients receiving 45- or 30-mg reduced to 15-mg upon achievement of ≤ 1% BCR::ABL1IS (≥ molecular response with 2-log reduction (MR2)). The exposure-molecular response relationship was described using a four-state, discrete-time Markov model. Time-to-event models were used to characterize the relationship between exposure and arterial occlusive events (AOEs), grade ≥ 3 neutropenia, and thrombocytopenia. Increasing systemic exposures were associated with increasing probability of transitioning from no response to ≥ MR1, and from MR1 to ≥ MR1, with odds ratios of 1.63 (95% confidence interval (CI), 1.06-2.73) and 2.05 (95% CI, 1.53-2.89) for a 15-mg dose increase, respectively. Ponatinib exposure was a significant predictor of AOEs (hazard ratio (HR) 2.05, 95% CI, 1.43-2.93, for a 15-mg dose increase). In the exposure-safety models for neutropenia and thrombocytopenia, exposure was a significant predictor of grade ≥ 3 thrombocytopenia (HR 1.31, 95% CI, 1.05-1.64, for a 15-mg dose increase). Model-based simulations predicted a clinically meaningful higher rate of ≥ MR2 response at 12 months for the 45-mg starting dose (40.4%) vs. 30-mg (34%) and 15-mg (25.2%). The exposure-response analyses supported a ponatinib starting dose of 45 mg with reduction to 15 mg at response for patients with CP-CML.
Insights
Optimizing ponatinib dosage for chronic phase-chronic myeloid leukemia (CP-CML) demonstrated that a 45-mg starting dose, reducible to 15 mg upon response, improved molecular response rates. This approach balances efficacy and safety in TKI-resistant CP-CML patients.
Area of Science:
- Hematology
- Pharmacology
- Clinical Trials
Background:
- Chronic phase-chronic myeloid leukemia (CP-CML) often requires treatment with tyrosine kinase inhibitors (TKIs).
- Ponatinib is an effective TKI for patients resistant to other TKIs or with the T315I mutation.
- Optimizing ponatinib dosing is crucial for maximizing efficacy while minimizing toxicity.
Purpose of the Study:
- To evaluate the dose-response and exposure-response relationships of ponatinib in CP-CML patients.
- To determine the optimal starting dose and dose reduction strategy for ponatinib in this population.
- To assess the impact of ponatinib exposure on molecular response and safety outcomes.
Main Methods:
- A randomized, phase II dose-optimization trial (OPTIC) involving CP-CML patients.
- Patients were randomized to starting ponatinib doses of 45 mg, 30 mg, or 15 mg daily.
- Markov models and time-to-event models were used to analyze exposure-response and exposure-safety relationships.
Main Results:
- Increased ponatinib exposure correlated with a higher probability of achieving molecular responses (MR1 and MR2).
- Ponatinib exposure was a significant predictor of arterial occlusive events (AOEs) and grade ≥3 thrombocytopenia.
- Simulations predicted higher rates of achieving MR2 at 12 months with a 45-mg starting dose (40.4%) compared to 30 mg (34%) and 15 mg (25.2%).
Conclusions:
- A starting dose of 45 mg ponatinib, with subsequent reduction to 15 mg upon achieving molecular response, is supported by exposure-response analyses.
- This dosing strategy appears to optimize the balance between efficacy and safety in TKI-resistant CP-CML patients.
- The findings provide evidence-based recommendations for ponatinib dosing in specific CP-CML patient populations.
More Related Videos
Related Concept Videos
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
01:12Analysis of Population Pharmacokinetic Data
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.